Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807415 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL18620099 | 0.83 | HTT (0.62) | SMN1; SMN2MEN1KMT2AALDH1A1PKM | |
| SCHEMBL9891528 | 0.83 | KMT2A (0.65) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL28676132 | 0.83 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL11515168 | 0.82 | MEN1 (0.73) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL11188939 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL629408 | 0.81 | CA1 (0.62) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL20762679 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL11489705 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL9892899 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | ASCENEURON SA (CH) | 2021-05-04 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| EP-2443107-B1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8846936-B2 | Sulfonyl compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ENGASE, GAA, GLA | SMN1; SMN2 1002/4885MEN1 3491/4885KMT2A 1095/4885 |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | SMN1; SMN2 3291/4885MEN1 1800/4885KMT2A 2881/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | SMN1; SMN2 3247/4885MEN1 1766/4885KMT2A 2554/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | SMN1; SMN2 3670/4885MEN1 3098/4885KMT2A 4530/4885 |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, GPR52 | SMN1; SMN2 4149/4885MEN1 4770/4885KMT2A 3333/4885 |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | SMN1; SMN2 4609/4885MEN1 4853/4885KMT2A 3143/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | SMN1; SMN2 4659/4885MEN1 4874/4885KMT2A 3551/4885 |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | SMN1; SMN2 748/4885MEN1 2369/4885KMT2A 1592/4885 |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | SMN1; SMN2 2327/4885MEN1 4030/4885KMT2A 1784/4885 |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | SMN1; SMN2 1002/4885MEN1 3491/4885KMT2A 1095/4885 |
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | GLA, BACE1, GAA | SMN1; SMN2 1710/4885MEN1 3158/4885KMT2A 1851/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | SMN1; SMN2 1710/4885MEN1 3158/4885KMT2A 1851/4885 |
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | GAA, ENGASE, BACE1 | SMN1; SMN2 1134/4885MEN1 4234/4885KMT2A 1534/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | SMN1; SMN2 1954/4885MEN1 2519/4885KMT2A 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.